+44 (0)1628 530554

News Feed


accelerated development | ADAPT SMART | Adaptive Licensing | adaptive pathways | antibiotic resistance | antibiotics | antimicrobial resistance | Article 57 database | ATMPs | AusPARs | BCS | Biosimilar Products | Biosimilars | biowaivers | CDSCO | Centralised Procedure | Certificates of Free Sale | clinical data | clinical trials | CMDh | COA | common repository | Common Technical Document | compliance | conditional marketing authorisation | DCP | Decentralised Procedure | e-cigarettes | eAFs | EAMS | early access | eCTD | EMA | EPARs | EU Telematics Strategy | EudraVigilance | European Clinical Trial Regulation | European Commission | FDA | Fees | GCP | gene therapy | GMP | Good Practice | Guidance | GVP | Herbal Medicinal Products | HMA | ICH | ICH E6 | IMP | in vitro medical devices | innovation | International Generic Drug Regulator Pilot | ISO 13485 | ISO ICSR | IVDs | legislation | M4E(R2) | M7 Guideline | MAAs | Manufacturing licences | marketing authorisation | Medical devices | Medical Devices Directive | Medical Devices Regulation | medical information | medical literature | medication errors | Medicines regulation | MHRA | Module V | MRP | Mutual Recognition Procedure | National Competent Authority | National Procedures | NICE | notification | Notified Bodies | Orphan Medicinal Products | paediatrics | PAES | PAR | patient safety | pharmacovigilance | PharmaLex UK | PharmaLex UK Services Limited | PIP | post-authorisation | post-authorisation safety studies | PRAC | Pre-authorisation | Press release | PRIME | Product information | PROTECT | PSMF | PSUR | PSURs | public register of parallel distribution | Publishing | QPPV | rare diseases | Scientific advice | seasonal flu vaccine | SMEs | Submissions | Third countries | Translations | Transparency | validation | Wainwright Associates Limited | Wholesale Distribution Authorisations | YES Pharma Services GmbH |


Feb 2017

On the 5th May 2017, the European Commission is hosting a multi-stakeholder workshop to develop a Q&A on the use of biosimilar medicines aimed at healthcare professionals. The session follows two previous workshops, where information has been gathered and subsequently shared to enhance patient understanding and trust of the use of biosimilars throughout Europe. The […]

read more
Jan 2017

The European Medicines Agency (EMA) is planning to launch a pilot project in February 2017 to assess the viability and value of customised scientific advice for the development of biosimilars. The new approach will provide a more in-depth assessment of the data concerning development to date, focussing on quality, analytics and function. The EMA hopes […]

read more
Dec 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) and the Human Tissue Authority (HTA) have signed an agreement which hopes to promote further collaboration between the two bodies. The strengthened partnership will cover the work carried out by both organisations in the UK, helping to ensure their approach to licensing and inspection is fair and […]

read more
Nov 2016

The Medicines and Healthcare products Regulatory Agency (MHRA) is leading an action to reinforce the market surveillance of medical devices by Competent Authorities. The Joint Action on Market Surveillance of Medical Devices aims to improve the coordination of activities by all Member States of the European Union (EU). The system also seeks to ensure adequate […]

read more
Nov 2016

The International Conference on Harmonisation (ICH) has recommended a new topic for the development of a guideline to support the use of the Biopharmaceutics Classification Systems (BCS)-based biowaivers in respect of bioequivalence studies. The new guideline will BCS-based biowaivers and result in harmonisation of current regional guidelines whilst supporting the streamlining of global drug development. […]

read more
Nov 2016

The European Medicines Agency (EMA) has now given open access to clinical reports for new medicines for human use that have been authorised in the European Union (EU). The public, including researchers and academics, will now be able to access the clinical reports submitted to the EMA as part of a marketing authorisation application. The […]

read more
Oct 2016

The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new working group to boost medicine development for rare diseases. The new ‘cluster’ on rare diseases will facilitate the sharing of experiences and best practices on regulatory approach. It will also enable the exchange of information on […]

read more
Loading posts...
Share On Facebook
Share On Twitter
Share On Google Plus
Share On Linkdin
Share On Pinterest